Features of ultrasound of endometrial pathological conditions in breast cancer patients receiving tamoxifen: a review of literature
https://doi.org/10.17650/1994-4098-2020-16-1-37-42
Abstract
The article examines the possibilities and features of ultrasound in the diagnosis of endometrial pathological conditions on the background of taking tamoxifen in women diagnosed with breast cancer based on data obtained from studying the sources of domestic and foreign literature from 1994 to 2018.
About the Authors
M. A. Chekalova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
M. I. Borisova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Bulgatova E.A. Evaluation of the endometrium in long-term users of tamoxifen with breast cancer. Summary of thesis … of candidate of medical sciences. Saint Petersburg, 2003. 20 p. (In Russ.).
2. Motskobili T.A. Capabilities of sonography and hysteroscopy in the diagnosis of endometrial pathology in patients with breast cancer receiving antiestrogen therapy for a long time. Summary of thesis… of candidate of medical sciences. Moscow, 2003. 27 p. (In Russ.).
3. Cohen I., Altaras M.M., Shapira J. et al. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol 1996;15(2):152–7. DOI: 10.1097/ 00004347-199604000-00010.
4. Cheng W.F., Lin H.H., Torng P.L., Huang S.C. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66(2):233–7. DOI: 10.1006/gyno.1997.4739.
5. NCCN clinical practice guidelines in oncology, v. 1.2008. Breast Cancer. Pp. 312–320.
6. Qureshi A., Bukhari F., Pervez S. Spectrum of tamoxifen associated endometrial pathology in breast cancer patients. J Pak Med Assoc 2009;59(4):249–50.
7. Negoiţă M., Terinte C., Mihailovici M.S. Tamoxifen and endometrial pathology. Rev Med Chir Soc Med Nat Iasi 2010;114(4):1114–7.
8. Sendag F., Sahin C., Zeybek B. et al. Retrospective analysis of hysteroscopic findings in breast cancer patients having adjuvant tamoxifen treatment. Eur J Gynaecol Oncol 2010;31(4):415–7.
9. Fornander T., Cedermark B., Mattson A. et al. Adjuvant tamoxifen in early breast cancer: occurence of new primary cancer. Lancet 1990;2:117–28. DOI: 10.1016/S0140-6736(89)91141-0.
10. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 2010;365:1687–717.
11. Golovkin E.U., Gosteva A.S., Ivashenko T.E. Changes in the endometrium on the background of hormone therapy for breast cancer. Proceedings of the University’s scientific conference dedicated to the 60th anniversary of the founding of the Ryazan State Medical University named after academician I.P. Pavlova on Ryazan land. Ryazan, 2010. Pp. 90–92. (In Russ.).
12. Jung H., Jung J.K., Kim S.B. et al. Comparative Study on Hysteroscopic and Histologic Examinations of the Endometrium in Postmenopausal Women Taking Tamoxifen. J Menopausal Med 2018;24(2):81–6. DOI: 10.6118/jmm.2018.24.2.81.
13. Lee S., Kim Y.H., Kim S.C. et al. The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer. Obstet Gynecol Sci 2018;61(5):615–20. DOI: 10.5468/ogs.2018.61.5.615.
14. Smith-Bindman R., Kerlikowske K., Feldstein V.A. et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998;4;280(17):1510–7. DOI: 10.1001/jama.280.17.1510.
15. Gardner F.J., Konje J.C., Brown L. et al. Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen. Climacteric 1998;1(3):180–7.
16. Cohen I., Azaria R., Bernheim J. et al. Comparison of endometrial pathologies collected by hysteroscopy and hysterectomy in postmenopausal breast cancer tamoxifen-treated patients. Eur J Gynaecol Oncol 2000;21(4):418–22.
17. Menada M.V., Papadia A., Lorenzi P. et al. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaecol Oncol 2004;25(3):321–3.
18. Salazar E.L., Paredes A., Calzada L. Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen. Gynecol Endocrinol 2005;21(6):312–6. DOI: 10.1080/09513590500430450.
19. Dijkhuizen F.P., Brölmann H.A., Oddens B.J. et al. Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Maturitas 1996;25(1):45–50.
20. Love C.D., Muir B.B., Scrimgeour J.B. et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999;17(7):2050–4. DOI: 10.1200/JCO.1999.17.7.2050.
21. Liedman R., Lindahl B., Andolf E. et al. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res 2000;20(6C):4889–91.
22. Marchesoni D., Driul L., Fabiani G. et al. Endometrial histologic changes in postmenopausal breast cancer patients using tamoxifen. Int J Gynaecol Obstet 2001;75(3):257–62.
23. Sin C.H., Kim S.A., Ki W.S. et al. The diagnostic role of hysteroscopy in postmenopausal bleeding. Korean J Obstet Gynecol 2007;50:1240–6.
24. Melnikova N.S., Kozlova O.V., Larionov O.V. Ultrasonic, hysteroscopic and histological evaluation of the endometrium in women receiving tamoxifen for breast cancer. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2013;(3–4):97–100. (In Russ.).
25. Pokharel H.P., Bhatla N., Kriplani A. et al. Evaluation of endometrial changes and p53 expression in tamoxifen treated women: comparison of various methods. Kathmandu Univ Med J (KUMJ) 2006;4(2):145–51.
26. Kazerooni T., Ghaffarpasand F., Mosalaei A., Kazerooni Y. The value of transvaginal ultrasonography in the endometrial evaluation of breast cancer patients using tamoxifen. Med Princ Pract 2010;19(3): 222–7. DOI: 10.1159/000285296.
27. McCluggage W.G., Desai V., Manek S. Tamoxifen-associated postmenopausal adenomyosis exhibits stromal fibrosis, glandular dilatation and epithelial metaplasias. Histopathology 2000;37(4):340–6.
28. Cheng W.F., Lin H.H., Torng P.L., Huang S.C. Comparison of endometrial changes among symptomatic tamoxifentreated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66(2):233–7. DOI: 10.1006/gyno.1997.4739.
29. Mehasseb M.K., Bell S.C., Habiba M.A. The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse. Reproduction 2009;138(2):341–50. DOI: 10.1530/REP-09-0054.
30. Taylor A.H., Kalathy V., Habiba M. Estradiol and tamoxifen enhance invasion of endometrial stromal cells in a three-dimensional coculture model of adenomyosis. Fertil Steril 2014;101(1):288–93. DOI: 10.1016/j.fertnstert.2013.09.042.
31. Alcázar J.L., Bonilla L., Marucco J. Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥11 mm: A systematic review and meta-analysis. J Clin Ultrasound 2018;46(9):565–70. DOI: 10.1002/jcu.22631.
32. Chekalova M.A., Makhova E.E., Shabanov M.A. et al. Significance of endometrial ultrasound monitoring in patients with breast cancer. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2007;(1–2):17–22. (In Russ.).
Review
For citations:
Chekalova M.A., Borisova M.I. Features of ultrasound of endometrial pathological conditions in breast cancer patients receiving tamoxifen: a review of literature. Tumors of female reproductive system. 2020;16(1):37-42. (In Russ.) https://doi.org/10.17650/1994-4098-2020-16-1-37-42
Views:
656
Email this article 